Oncolytics Biotech Inc Announces Enrollment in Phase II Study of Reolysin for Pancreatic Cancer

Strategic Insights -

Oncolytics Biotech Inc has announced that enrollment has begun in a Phase II study of its oncolytic virus Reolysin in combination with standard chemotherapy carboplatin and paclitaxel for the treatment of patients with recurrent or metastatic pancreatic cancer. The study aims to assess the efficacy of Reolysin in improving progression-free survival compared to standard chemotherapy alone. The trial is sponsored by the US National Cancer Institute and will enroll approximately 70 patients.

Key Takeaways:

  • The Phase II study is a 2-Arm randomized trial, with patients receiving either carboplatin, paclitaxel plus Reolysin (Arm A) or carboplatin and paclitaxel alone (Arm B).
  • Patients in both arms will receive treatment every three weeks, with tumour response assessment every eight weeks.
  • The primary objective of the trial is to assess improvement in progression-free survival with Reolysin, carboplatin, and paclitaxel relative to carboplatin and paclitaxel alone.
  • The secondary endpoints include overall response rate and overall survival.
  • The study involves approximately 70 patients and is sponsored by the US National Cancer Institute.
  • The Principal Investigator is Dr. Tanios Bekaii-Saab, Medical Director of Gastrointestinal Oncology at The Ohio State University Comprehensive Cancer Center.

Statistics:

  • The study is expected to enroll approximately 70 patients.
  • The trial will involve a treatment duration of 21-day cycles, with tumour response assessment every 8 weeks.
  • The primary endpoint is progression-free survival in both arms.

Sources:

  • Oncolytics Biotech Inc
  • The Ohio State University Comprehensive Cancer Center - Arthur G James Cancer Hospital and Richard J Solove Research Institute
  • US National Cancer Institute (NCI), Division of Cancer Treatment and Diagnosis
  • National Institutes of Health